Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP450 for Crow's Feet and Glabellar Lines
NCT03184363Phase 3Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Oct 2017
01
Overview
Phase 3, open-label, single-arm trial of prabotulinumtoxinA in glabellar lines, sponsored by Daewoong Pharmaceutical. Primary endpoint: Subject Assessment of Satisfaction of Appearance at 4 weeks. Status: unknown.
02
Drugs
prabotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03184363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184363.